PETER D STAPLE
CIK 1271088 · President & CEO · last filed 2024-05-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$9.07M
Companies
3
Total Filings
47
Lifetime Open-Market Net
-$411.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ASRT | Director | 385,761 | $23.50 | $9.07M | $9.9K | 7 | 2024-05-28 |
| Corium International, Inc. (CORI) Delisted | President & CEO | 0 | — | — | -$538.5K | 15 | 2018-11-28 |
| Assertio Therapeutics, Inc (DEPO) Delisted | Director | 201,937 | — | — | $117.6K | 25 | 2018-05-10 |
Recent Filings · Page 5 of 5
47 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-05-13 | Assertio Therapeutics, Inc (DEPO) Delisted | Buy (P) | +5,000 | $40.7K | EDGAR |
| 2010-12-13 | Assertio Therapeutics, Inc (DEPO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-12-08 | Assertio Therapeutics, Inc (DEPO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-06-15 | Assertio Therapeutics, Inc (DEPO) Delisted | Buy (P) | +5,000 | $13.4K | EDGAR |
| 2009-03-12 | Assertio Therapeutics, Inc (DEPO) Delisted | Buy (P) | +5,000 | $10.0K | EDGAR |
| 2008-12-10 | Assertio Therapeutics, Inc (DEPO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-12-07 | Assertio Therapeutics, Inc (DEPO) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 41–47 of 47
Prev
Page 5 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.